KB-1276

AMG305-MSLN-hIgG1

Home » Antibody » AMG305-MSLN-hIgG1

Background

Mesothelin (MSLN) is a differentiative antigen that is highly expressed in several human tumors, including mesothelioma, ovarian, and pancreatic cancers. As MSLN is overexpressed only in tumor tissues and not in adjacent normal tissues in pancreatic cancer, and is closely associated with tumor progression and migration, it has been proven to be a promising cancer biomarker and an effective target for cancer-targeted therapy.Modification with an anti-MSLN antibody would improve the targeting efficiency of diagnostic imaging agents and the drug-delivery system towards the MSLN-overexpressing pancreatic tumors.

Specifications

Catalog Number:
KB-1276
Cell Line Name:
AMG305-MSLN-hIgG1
Price:
0
Host Cell Line:
EXPI-CHO
Target:
MSLN
Species Reactivity:
Human
Application:
ELISA | FACS
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA | FACS

References

1.Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overex-pressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862-3862. 2.Ord¨®?ez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27:1418-1428. 3.Roe OD, Creaney J, Lundgren S, et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer. 2008;61:235-243. 4.Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10(12 Pt 1):3937-3942.7
Please enable JavaScript in your browser to complete this form.